Summary
Signal counts
Assets tracked: 6
Watchlist assets: 5
Registry stop assets: 2
Sponsor overview
Chia Tai Tianqing Pharmaceutical Group Co., .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT04398953 | https://clinicaltrials.gov/study/NCT05481645 | https://clinicaltrials.gov/study/NCT06218771 | https://clinicaltrials.gov/study/NCT04924192 | https://clinicaltrials.gov/study/NCT05859373 | https://clinicaltrials.gov/study/NCT07367516
Assets
Linked programs
- TQ-B3525: Timeline Staleness Signal (3/5)
- TQB2450 injection: Registry Stop Signal (4/5)
- TQB3454 Tablets: Timeline Staleness Signal (3/5)
- TQB3616 capsules: Registry Stop Signal (3/5)
- TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation: Timeline Staleness Signal (4/5)
- TQB6411 Injection: Low Signal (0/5)